Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma

Leuk Lymphoma. 2005 Dec;46(12):1807-11. doi: 10.1080/10428190500233764.


Denileukin diftitox (DAB(389)IL-2 or Ontak) is a synthetic fusion protein with demonstrated efficacy in a number of lymphoproliferative disorders, including non-Hodgkin's lymphoma. We report the case of a 45-year-old man with progressive follicular large cell lymphoma following an autologous stem cell transplant treated with denileukin diftitox who developed a fatal skin rash associated with extensive erythema, edema and large bullae involving his entire body. The clinical features and pathology were compatible with toxic epidermal necrolysis. This is the first reported case of toxic epidermal necrolysis in the literature associated with denileukin diftitox.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Black People
  • Dermatitis / pathology
  • Diphtheria Toxin / adverse effects*
  • Fatal Outcome
  • Humans
  • Interleukin-2 / adverse effects*
  • Lymphoma, Follicular / drug therapy*
  • Lymphoma, Follicular / pathology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Recombinant Fusion Proteins / adverse effects
  • Stevens-Johnson Syndrome / pathology*
  • Texas


  • Antineoplastic Agents
  • Diphtheria Toxin
  • Interleukin-2
  • Recombinant Fusion Proteins
  • denileukin diftitox